Curated news and analysis on clinical trials, drug approvals, and medical research.
Recent CAR T-cell therapy studies report durable 10-year remissions in lymphoma, healthy pregnancies in autoimmune disease patients, and a 44% response rate in liver cancer. Infection risk and iron-driven ferroptosis are key challenges, while off-the-shelf CAR T programs advance.
The Astera Institute invests $500M in Radial to build AI-friendly biology infrastructure. Meanwhile, AI tools flood computer science publishing, AI-assisted NIH grants lean toward less innovation, and a new platform lets AI agents hire human helpers.
The Trump administration’s proposed 2027 insurance regulation omits copay accumulator protections, allowing insurers and PBMs to continue diverting billions in manufacturer copay assistance from patients. Advocates warn that without action, rising out-of-pocket costs will further strain patients. The rule also fails to close a loophole for large group plans regarding essential health benefits.
Novartis AG is selling its 70.68% controlling stake in Novartis India to ChrysCapital for $175 million, triggering a mandatory open offer at INR 860.64 per share. Shares surged 20% as the Swiss drugmaker shifts investment to US manufacturing amid tariff risks.
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
The Trump administration is terminating a $3.6 billion subsidy program for Medicare Part D premiums, potentially raising costs for millions of seniors. The CMS administrator confirmed the subsidies will end after 2026, affecting roughly 75% of the 25 million beneficiaries with possible out-of-pocket increases.
In 2025, China's NMPA approved 289 new drug applications, including traditional Chinese medicines. A study reveals critical methodological gaps in clinical trials of herbal therapies, while a review highlights the potential of nanoformulations for renal fibrosis.
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
Zemcelpro (dorocubicel) has achieved NUB Status 1 in Germany, enabling hospitals to seek temporary reimbursement, while Cordex Biologics expanded access to Asia and Argentina through a distribution deal with FarmaMondo. The cell therapy holds conditional EU authorization for certain blood cancers.
When a parent is diagnosed with cancer, Mount Sinai’s Child Life and Creative Arts Therapy team offers age-appropriate, therapeutic support to help children cope. Services include education, play activities, and art therapy, fostering communication and resilience.
The FDA granted RMAT designation to Allogene’s cema-cel for first-line LBCL consolidation and Cellectis’ lasme-cel for r/r B-ALL. Both allogeneic CAR-T therapies showed promising early efficacy and safety, with cema-cel also receiving Fast Track status.
Phase 3 PROTEUS: perioperative apalutamide plus ADT met both dual primary endpoints in high-risk localized prostate cancer, raising pCR/MRD rates to 8.9% vs 1.0% and cutting metastasis or death risk by 20%.
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
ChrysCapital-led open offer for Novartis India saw only 40 shares accepted. The consortium acquired Novartis AG's 70.68% stake for Rs 1,445.8 crore; public shareholding now stands at 29.32%.
Researchers have developed an integrated live-cell imaging and cytometry workflow to monitor brain organoid differentiation. Separately, experiments on the International Space Station show that microgravity accelerates organoid aging by roughly a decade in 30 days, offering a faster model for neurodegenerative diseases. These advances could enhance drug discovery and neurodevelopmental research.
On June 8, 2026, the U.S. Department of War added Alibaba, BYD, and WuXi AppTec to its Section 1260H list, triggering BIOSECURE Act risks for U.S. biotechs with federal contracts using WuXi’s services.
A review and two studies report advances in nanomaterial-based cancer immunotherapy, including engineered nanoparticles that boost immunogenic tumor cell death, nanosheet artificial antibodies that block PD-L1, and design principles for overcoming delivery barriers. These approaches aim to improve immune activation and reduce off-target effects.
The FDA granted Fast Track Designation to Quoin's QRX003 for Netherton Syndrome and supported NRx's NRX-100 NDA path under Fast Track for treatment-resistant depression, addressing serious unmet needs.
FDA granted rolling review for Palvella's QTORIN rapamycin NDA. Also covered: global expedited approval pathways, accelerated approval scrutiny, and multi-regional CDx strategies.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
